OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving ...

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation Completion of Tedopi’s phase 3 in Non-Small Cell Lung Cancer One or two new rare/specialty ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

Investing.com -- Ose Immunotherapeutics stock dropped 4.25% following an announcement that the company has amended its ...

Podcast host Mel Robbins mentions multiple unique factors that cause stress for people in their 20s and offers advice on how ...

Half advice show. Half survival guide. Half absurdity-fest. (Wait, how does this work again? We're not numbers people.) Each episode, we answer all your burning questions, from how to survive a public ...

On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important ...

HAMILTON, Bermuda, Dec. 8, 2025 /PRNewswire/ — Borr Drilling Limited (NYSE: BORR) (the “Company”) announces today its plans to raise approximately $85 million in gross proceeds though an offering of ...

Biopharma happenings, including deals and partnerships, and other news in brief: Abeona, Abbvie, Ayrmid, Evotec, Kamada, OSE, Sandoz.

Alberta hospitals are being slammed with flu patients at a time when they’re already under strain, and doctors are bracing ...

As economies and capital markets across the Asia-Pacific region mature, firms are moving beyond rapid expansion to focus on sustained, long-term shareholder value. This is according to a new report ...

Great for Hanukkah, 'The Tourist’s Guide to Lost Yiddish New York City' by Henry H. Sapoznik is not your usual guidebook. In fact, many of the sites listed in it haven't existed for decades ...